Eubel Brady & Suttman Asset Management Inc. Grows Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Eubel Brady & Suttman Asset Management Inc. lifted its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 229,375 shares of the medical equipment provider’s stock after purchasing an additional 6,372 shares during the quarter. Zimmer Biomet comprises 3.6% of Eubel Brady & Suttman Asset Management Inc.’s investment portfolio, making the stock its 8th biggest holding. Eubel Brady & Suttman Asset Management Inc. owned about 0.11% of Zimmer Biomet worth $24,894,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. OLD Point Trust & Financial Services N A bought a new position in Zimmer Biomet in the 4th quarter valued at about $26,000. Ables Iannone Moore & Associates Inc. bought a new position in Zimmer Biomet in the 4th quarter valued at about $30,000. Crewe Advisors LLC bought a new position in Zimmer Biomet in the 1st quarter valued at about $31,000. Family Firm Inc. bought a new position in Zimmer Biomet in the 2nd quarter valued at about $33,000. Finally, J.Safra Asset Management Corp lifted its position in Zimmer Biomet by 712.1% in the 1st quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 235 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH opened at $104.83 on Tuesday. The stock has a market cap of $21.35 billion, a PE ratio of 22.69, a PEG ratio of 1.92 and a beta of 1.02. The company’s fifty day moving average is $110.01 and its 200 day moving average is $116.63. Zimmer Biomet Holdings, Inc. has a 52 week low of $102.00 and a 52 week high of $133.90. The company has a quick ratio of 0.63, a current ratio of 1.29 and a debt-to-equity ratio of 0.31.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.02. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. The company had revenue of $1.94 billion for the quarter, compared to analysts’ expectations of $1.94 billion. During the same quarter last year, the company earned $1.82 EPS. The firm’s revenue was up 3.9% compared to the same quarter last year. Research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.02 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.92%. The ex-dividend date is Monday, September 30th. Zimmer Biomet’s payout ratio is 20.78%.

Wall Street Analyst Weigh In

Several equities research analysts have commented on ZBH shares. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research note on Thursday, August 8th. Barclays decreased their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an “underweight” rating for the company in a research note on Friday, May 31st. Wolfe Research began coverage on shares of Zimmer Biomet in a research note on Tuesday. They issued a “peer perform” rating for the company. UBS Group decreased their price target on shares of Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating for the company in a research note on Thursday, August 8th. Finally, Citigroup decreased their price target on shares of Zimmer Biomet from $134.00 to $120.00 and set a “neutral” rating for the company in a research note on Wednesday, July 10th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and an average price target of $126.00.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.